Evaluation of the Effects of Dietary n-3 Fatty Acid Supplementation on the Pharmacokinetics of Doxorubicin in Dogs with Lymphoma

Source: Kim A. Selting, DVM, MS; Gregory K. Ogilvie, DVM; Daniel L. Gustafson, PhD; Michael E. Long, BS; Susan E. Lana, DVM, MS; Judy A. Walton; Rodney A. Hansen, PhD; A. Simon Turner, BVSc, MS; Irene Laible, BA; and Martin J. Fettman, DVM, PhD

To determine the effect of dietary n-3 fatty acids on the pharmacokinetics of doxorubicin in dogs with lymphoma. Animals—23 dogs with lymphoma in stages IIIa, IVa, and Va. Procedure—Dogs receiving doxorubicin chemotherapy were randomly allocated to receive food with a high (test group) or low (control group) content of n-3 fatty acids. Serum doxorubicin and doxorubicinol concentrations were measured via highperformance liquid chromatography before and 6 to 9 weeks after initiation of the diets. Lymph node concentrations of doxorubicin were assessed 6 hours after the initial treatment. Dogs' body composition was assessed by means of dual-energy x-ray absorptiometry scans.

Full Article »

Foward to an Associate